Neuronetics: A Real Platform Turnaround, Already Mostly Priced In

On September 11, B. Riley initiated coverage of Neuronetics (NASDAQ: STIM) with a Buy rating at roughly $3 and a $5 price target, on a stock that had already more than doubled this year. A Buy call on a name that big of a run is either a late call or a signal that the re-rating is only beginning. The difference depends on what the company has quietly become.

Once a medical-device seller best known for NeuroStar, its transcranial magnetic stimulation (TMS) system for treatment-resistant depression, Neuronetics bought the clinic network Greenbrook TMS in late 2024. That one deal changed the business. Today it both sells the machines and runs the clinics that use them — roughly 92 company-owned centers, all delivering the same depression therapy. Wall Street now calls the combination a vertically integrated "interventional psychiatry platform," and the whole bull case rests on that rename being more than branding.

The unused-capacity story is the engine

Management says the clinics have about 40% of their capacity sitting empty. For a clinic business that is the entire investment thesis in one number: the machines, the buildings, and most of the staff are already paid for, so every filled treatment slot is largely dropped to the bottom line. That is the "operating leverage" B. Riley argues will translate disproportionately into earnings — the same session that lifts revenue barely lifts costs.

The most recent quarter shows the machine starting to work. In Q2 2026, total revenue rose 9.1% to $41.6 million, and the company posted its first positive adjusted EBITDA at $0.3 million, versus a $5.6 million loss a year earlier. Gross margin climbed to about 51% from 46.6%, and the GAAP net loss narrowed from $10.1 million to $3.4 million. It also changed leadership this year — a new CEO in March and a new CFO in July — a reset the B. Riley note compresses into "management reset."

The growth is not coming from the flagship line

Here is the strongest bear fact against the story: the growth is not coming from the product that gave the company its name. NeuroStar device revenue actually fell 2.7% in the quarter to $14.7 million, because management is rewriting how the equipment is sold — moving from treatment-session partnerships toward lease and outright-purchase options, a transition that has not proven itself. Every bit of the growth came from the clinic side, up 16.8% to $26.9 million. In other words, the "platform" is expanding by filling up what it bought, while the original device business shrinks beneath it.

That distinction matters for the math. On the surface the valuation looks undemanding: roughly $277 million in enterprise value against about $160–164 million of guided full-year revenue, and B. Riley pegs the stock at around 1.5x estimated 2028 enterprise value to sales versus roughly 2.4x for peers. The market, in other words, still prices Neuronetics like a struggling device maker rather than a scaled clinic platform. But cheap on sales is not cheap on earnings, and this is where the balance sheet enters.

Cash on hand was about $25 million at the end of June, down from $34 million at the start of the year, against $61.5 million of net long-term debt. Management guided 2026 cash flow from operations and investing to a negative $10.5 million to $14.5 million, and B. Riley itself flags debt-covenant issues that still need resolving. The turnaround must keep generating cash quickly; the cushion is thin.

The 2027 swing factor is not yet in hand

The deeper reason for the "interventional psychiatry" framing is psychedelics. The expected FDA decision on Compass Pathways' COMP360 psilocybin therapy, possibly by the end of 2026, could open a new treatment wave that these clinics — with their empty capacity — are positioned to capture, and Neuronetics already has the infrastructure from administering the nasal esketamine drug Spravato. But approval is not here yet. B. Riley's $5 target, the firm says, normalizes Neuronetics toward fair-value benchmarks with only minimal psychedelic contribution; the firm sees approvals of COMP360 and subsequent drugs as potential catalysts that could justify a premium multiple, but those have not been cleared.

This is a genuine turnaround, and the evidence for it is real: the EBITDA inflection, the margin gains, and the capacity story are all visible. But the stock has already moved through much of that story this year, the growth is being carried by an acquired clinic network while the flagship product line contracts, and the balance sheet leaves little room for error. At $3, the Buy case asks you to underwrite continued proof over the next two to four quarters — sustained positive EBITDA, Greenbrook filling that idle capacity, NeuroStar stabilizing. Treat B. Riley's $5 as the bull case, not a guarantee, and let the quarterly results, not the analyst report, supply the evidence before deciding.